Company Overview
Outset Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it engages in the development and provision of a hemodialysis system designed for use in the United States. The company offers the Tablo Hemodialysis System, a compact console that features integrated water purification, on-demand dialysate production capabilities, and proprietary software solutions. The organization maintains a workforce of 310 employees and holds a total market capitalization of $65.19 million. While the company has generated annual revenue of $119.48 million, the market cap figure indicates a valuation that is significantly lower than its total revenue generation, suggesting the market prices the stock based on future profitability expectations rather than current earnings power. This disparity between the substantial revenue base and the relatively modest market cap reflects the high-risk nature of the medical device sector, where investors often discount assets that are not yet profitable. The scale of operations, supported by nearly $169 million in cash reserves, positions the company to pursue aggressive expansion or research initiatives despite the current lack of net income.
Financial Health
The company reported revenue of $119.48 million over the trailing twelve months, yet it posted a net income loss of $81,653,000 and an EBITDA loss of $62,373,000. The significant gap between the positive revenue and the substantial net loss reveals a heavy cost structure, likely driven by high research and development expenses, sales and marketing costs, or operational inefficiencies that consume the majority of top-line income. Free cash flow stands at $-21,346,250, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund operations solely from internal cash flows without external financing. Despite the negative operating performance, the balance sheet shows a robust cash position of $168.95 million against total debt of $101.25 million, which provides a significant liquidity buffer. However, the debt-to-equity ratio is 79.75, a metric that suggests the company is highly leveraged relative to its equity base, though the absolute cash holdings mitigate immediate solvency risks. The current ratio of 6.67 indicates strong short-term liquidity, as the company holds more than six times the value of its current liabilities in current assets. Return on Equity is -106.2% and Return on Assets is -15.4%, metrics that reveal that management has not yet been able to generate positive returns on the capital invested in the business. These negative return figures highlight the early-stage or growth-phase challenges the company faces in translating its technological capabilities into profitable financial performance.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the negative earnings, while the forward P/E is listed as -1.52. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market expects the company to remain unprofitable for the foreseeable future, preventing any traditional earnings-based valuation from applying. The price-to-book ratio is 0.51, indicating that the stock trades at roughly half its book value, which suggests the market is valuing the company well below the replacement cost of its assets. The price-to-sales ratio is 0.55, and the EV/EBITDA is 0.04; these alternative valuation metrics suggest that investors are pricing the stock primarily on its revenue potential and asset base rather than current profitability. The 52-week high is $21.98 and the 52-week low is $3.00, meaning the current price sits significantly below the yearly peak, reflecting the volatile sentiment surrounding the stock. With a beta of 2.10, the stock exhibits price volatility that is more than twice as high as the broader market, indicating that the share price is highly sensitive to market movements and investor sentiment regarding the medical device sector.
Growth & Income
Revenue growth year-over-year is -2.0%, while earnings growth is N/A due to the lack of positive earnings in the prior period. The absence of positive earnings growth means that profitability is not currently growing faster or slower than revenue; rather, the company is operating at a loss where revenue contraction is a primary concern. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Because the company is not a dividend payer, it reinvests its limited retained earnings and cash reserves back into the business to fund research, development, and market expansion rather than distributing income to shareholders. The overall growth and income profile is characterized by revenue contraction and a complete absence of current income distribution, relying entirely on the $168.95 million cash balance to sustain operations while searching for a path to profitability.